Interestingly, Boutros et al. [80] suggested that BRAF/MEK inhibitors + anti-PD(L)1 had a higher probability of achieving better PFS and ORR compared with ipilimumab + nivolumab for the treatment of advanced melanoma. This evidence concerns the gene BRAF and melanoma.